Clinical trial
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
NCT00402818 · Merck KGaA, Darmstadt, Germany, Industry · Terminated
Key facts
| NCT number | NCT00402818 |
|---|---|
| Title | RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization |
| Official title | RESTORE (Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-label, Multi-centre, Phase IV Study of Subcutaneously Administered Raptiva® (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates… |
| Acronym | RESTORE |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Plaque Psoriasis |
| Enrollment | 294 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | Aug 29, 2014 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: